Clinical Trials Logo

Leishmaniasis, Visceral clinical trials

View clinical trials related to Leishmaniasis, Visceral.

Filter by:

NCT ID: NCT03399955 Recruiting - Clinical trials for PKDL - Post-Kala-Azar Dermal Leishmanioid

Short Course Regimens for Treatment of PKDL (Sudan)

Start date: May 9, 2018
Phase: Phase 2
Study type: Interventional

This is an open label, randomized non comparative phase II clinical trial conducted on parallel groups, to assess the safety and efficacy of the combination of Paromomycin (20 mg/kg/d) IM for 14 days and Miltefosine (allometric dosing) oral for 42 days, and a combination of AmBisome® (20 mg/kg total dose) IV over 7 days and Miltefosine oral for 28 days (allometric dosing) for the treatment of PKDL patients in Sudan.

NCT ID: NCT01138956 Recruiting - Treatment Clinical Trials

Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine

VLNAC
Start date: April 2010
Phase: N/A
Study type: Interventional

This study is designed to evaluate the immune and therapeutic responses of visceral leishmaniasis patients using N-acetylcysteine (NAC) as an adjuvant therapy to pentavalent antimony.